IceCure Medical Ltd (NASDAQ:ICCM - Free Report) - Equities researchers at Brookline Capital Management upped their FY2025 earnings per share estimates for IceCure Medical in a note issued to investors on Monday, May 5th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($0.17) for the year, up from their prior forecast of ($0.25). The consensus estimate for IceCure Medical's current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical's FY2026 earnings at ($0.06) EPS, FY2027 earnings at $0.07 EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.32 EPS.
Separately, HC Wainwright restated a "buy" rating and set a $2.50 price target on shares of IceCure Medical in a report on Friday, March 28th.
Get Our Latest Research Report on ICCM
IceCure Medical Trading Up 4.2%
NASDAQ:ICCM traded up $0.04 during mid-day trading on Thursday, reaching $1.01. 395,145 shares of the company's stock traded hands, compared to its average volume of 328,588. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The firm has a market capitalization of $56.07 million, a price-to-earnings ratio of -3.48 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27. The company has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.11.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The company had revenue of $1.07 million during the quarter, compared to analysts' expectations of $1.07 million.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC grew its position in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 40,453 shares of the company's stock after acquiring an additional 14,893 shares during the period. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
